Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase 1 46Phase 3 16Phase 1/2 6Phase EARLY_PHASE1 5Phase 4 2Phase NA 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

Exercise 216Blood Specimen Collection 122Surveys and Questionnaires 117Standard of Care 114Magnetic Resonance Spectroscopy 113Early Intervention, Educational 108Educational Status 102Methods 101Radiotherapy 94Radiosurgery 76Counseling 72Control Groups 64Biopsy 61Acupuncture Therapy 60Therapeutics 57Psychiatric Rehabilitation 55Resistance Training 52Saline Solution 49Cyclophosphamide 48Palliative Care 46Practice Guidelines as Topic 41Cognitive Behavioral Therapy 41Yoga 40Metformin 40Interviews as Topic 40Drug Therapy 37Surgical Procedures, Operative 36Radiofrequency Ablation 35Dexmedetomidine 35Colonoscopy 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Completed × olaparib × Clear all
NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

University Health Network, Toronto

Phase NA Completed
34 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡